ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO028

Using Telemedicine Compared with Face-to-Face Visits for Outpatient Management in CKD Patients

Session Information

Category: Augmented Intelligence, Digital Health, and Data Science

  • 300 Augmented Intelligence, Digital Health, and Data Science


  • Apibankurukit, Nichapat, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand
  • Chuasuwan, Anan, Bhumibol Adulyadej Hospital, Bangkok, Bangkok, Thailand

In the recent past, Coronavirus disease 2019 (COVID-19) was a pandemic. Telemedicine is thought to be used for outpatient management in chronic kidney disease (CKD) patients because we want to reduce hospital visits and congestion in CKD clinic to decrease the risk of COVID-19 infection in CKD patients. This study aimed to compare the effectiveness of telemedicine with face-to-face visits for outpatient management in CKD patients.


A non-inferiority, non – randomized open-label controlled trial in a CKD clinic at Bhumibol Adulyadej Hospital, Bangkok, Thailand from January 2022 to January 2023. The patients were divided into 2 groups, using telemedicine and face-to-face visits. The primary outcome was to compare the percentage change of eGFR-EPI between the two groups.


There were 32 patients in both the telemedicine and face-to-face visit groups. The majority were male 60.9%. The mean age was 72.2 ± 11.2 (SD) years. CKD KDIGO stage 4 was the majority by 56.2% and mean eGFR-EPI was 24.6 ± 9.9 (SD) ml/min/1.73 m2. The eGFR increased by 2.1% in the telemedicine group and decreased by 2.1% in the face-to-face visits group (p 0.374). There was no difference between the two groups in all-cause mortality, hospitalization, emergency department visits, renal replacement therapy initiation rate, co-morbidities and CKD complications controlled, adherence, and satisfaction with the service. Telemedicine had higher quality of life, measured from the EQ-5D scales (69.5 vs 58.4 scores, p = 0.009), and used shorter timing in the visit (52.5 vs 189.5 minutes, p < 0.001) than the face-to-face visits group.


Compared to face-to-face visits, telemedicine for outpatient management in CKD patients is not inferior in the percentage change of eGFR, co-morbidities, and CKD complications. Telemedicine tends to have a better quality of life, shorten the timing of the visit, and lower travel costs to the hospital.


  • Government Support – Non-U.S.